Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1435178 | 0.91 | PDE4B (0.41) | PDE4BPDE4D | |
| SCHEMBL1435095 | 0.85 | PDE4B (0.55) | PDE4BPDE4D | |
| SCHEMBL1434787 | 0.84 | PDE4B (0.41) | PDE4BPDE4D | |
| SCHEMBL1435715 | 0.83 | PDE4B (0.52) | PDE4B | |
| SCHEMBL3426238 | 0.82 | PDE4B (0.56) | PDE4B | |
| SCHEMBL4508317 | 0.82 | PDE4B (0.62) | PDE4BPDE4D | |
| SCHEMBL1434958 | 0.82 | PDE4B (0.54) | PDE4B | |
| SCHEMBL1434829 | 0.81 | PDE4B (0.51) | PDE4B | |
| SCHEMBL4523542 | 0.81 | PDE4B (0.58) | PDE4B | |
| SCHEMBL1434714 | 0.80 | PDE4B (0.62) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940835-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131431-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors | PDE4B, PDE3B, PDE4A | PDE4B 1/4885PDE4D 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.